The mechanistic action of bromodomain-containing protein 4 (BRD4) in cancer motility, including epithelial-mesenchymal transition (EMT), remains largely undefined. We found that targeted inhibition of BRD4 reduces migration, invasion, in vivo growth of patient-derived xenograft (PDX), and lung colonization of breast cancer (BC) cells. Inhibition of BRD4 rapidly decreases the expression of Snail, a powerful EMT transcription factor (EMT-TF), via diminishing its protein stability and transcription. Protein kinase D1 (PRKD1) is responsible for BRD4-regulated Snail protein stability by triggering phosphorylation at Ser11 of Snail and then inducing proteasome-mediated degradation. BRD4 inhibition also suppresses the expression of Gli1, a key transductor of Hedgehog (Hh) required to activate the transcription of SNAI1, in BC cells. The GACCACC sequence (−341 to −333) in the SNAI1 promoter is responsible for Gli1-induced transcription of SNAI1. Clinically, BRD4 and Snail levels are increased in lung-metastasized, estrogen receptor-negative (ER-), and progesterone receptor-negative (PR-) breast cancers and correlate with the expression of mesenchymal markers. Collectively, BRD4 can regulate malignancy of breast cancer cells via both transcriptional and post-translational regulation of Snail.
Introduction
Bromodomain-containing protein 4 (BRD4) is a member of the BET (Bromodomain and Extra-Terminal) family proteins [1] . It interacts primarily with acetylated histone H4 at lysine (K) residues 5, 8, 12 and/or 16 and acetylates histone H3 at K9 and/or K14, via its tandem bromodomains, and recruits the transcription machinery to regulate gene expression [2, 3] . BRD4 can also occupy distal enhancer RNA (eRNA) regions to regulate transcription initiation and elongation [4] . Since BRD4 is a potential epigenetic therapeutic target, inhibitors of BET are currently in different phases of preclinical and clinical trials for treatment of multiple tumors [5] . Targeted inhibition of BRD4 can suppress growth and induce apoptosis of various cancer cells, including acute myeloid leukemia [6] , diffuse large B cell lymphoma [7] , prostate cancer [8] , and breast cancer [9] .
The roles of BRD4 in cancer metastases are largely unknown. Recent studies revealed that BRD4 can regulate cell motility via regulating Jagged1/Notch1 signaling [10] and interacting with epithelial-mesenchymal transition (EMT) transcription factor (EMT-TF) Twist [11] . EMT is a process by which epithelial cells gain a migratory and invasive mesenchymal phenotype [12] . EMT-TFs, including Twist, Snail, and Zeb1, can trigger the progression of EMT and promote cancer metastasis [13] . Expression of Snail (encoded by SNAI1), a key transcriptional repressor of E-cadherin expression in EMT, is epigenetically regulated by chromatin modifiers such as lysine-specific deme-thylase1 (LSD1) [14] and Suv39H1 histone methyltransferases [15] . Our recent study revealed that targeting CDK7 increases the stability of Snail to promote colorectal cancer dissemination [16] . The second bromodomain of BRD4 can intact with diacetylated EMT-TF Twist and then activate downstream genes [11] . Considering that BRD4 function is highly context-dependent, we are interested in determining the roles of BRD4 and its regulatory effects on EMT-TFs and dissemination of breast cancer (BC) cells. JQ1, a small molecule inhibitor of BRD4 [17] , has been widely used to investigate the roles of BET proteins [9, [18] [19] [20] . In the present study, we evaluated the potential roles of targeted inhibition of BRD4 by the use of JQ1 and its specific siRNA. We found BRD4 was involved in in vitro and in vivo dissemination of BC cells. Targeted inhibition of BRD4 also suppressed EMT progression via protein kinase D1 (PRKD1)-mediated post-translational and Gli1-mediated transcriptional downregulation of Snail.
Results

BRD4 is upregulated in BC and modulates the malignancy of cancer cells
We first measured the expression of BRD4 in various cells. Both mRNA ( Fig. S1A ) and protein ( Fig. 1a ) levels of BRD4 in BC cell lines were greater than that of nontumorigenic BC cell lines (HBL100 and MCF-10A). Consistently, increased expression of BRD4 in BC versus normal tissue has been observed in TCGA, Crutis, and Finak data from Oncomine databases ( Fig. 1b ), suggesting BRD4 is generally upregulated in BC cells and tissues.
We then evaluated the potential roles of BRD4 using BET bromodomian inhibitor JQ1. JQ1 >5 μM significantly decreased the proliferation of BC cells (Fig. S1B ). Further, JQ1 (1 μM, which had no effect on cell proliferation, Fig. S1B ) significantly inhibited the migration of MDA-MB-231 cells, even in the presence of TGF-β, which could induce EMT of cancer cells ( Fig. 1c) . Similarly, JQ1 inhibited the migration of BT-549 cells in the absence or presence of TGF-β ( Fig. S1C ). Transwell assay confirmed that JQ1 could inhibit the invasion of BC cells ( Fig. 1d ). To avoid the off-target effect of JQ1, we knocked down the expression of BRD4 using two specific siRNAs ( Fig. S1D ). si-BRD4 significantly inhibited the migration of BC cells (Fig. 1e ). However, knockdown of BRD2 and BRD3 ( Fig. S1E ), which are also inhibited by JQ1, had no effect on cell migration (Fig. S1F ). Conversely, overexpression of BRD4 ( Fig. S1G ) triggered wound closure of BC cells (Fig. 1f ).
The mesenchymal marker fibronectin (FN) was checked in JQ1-treated BC cells. JQ1 inhibited the expression of FN and further blocked TGF-β-induced FN in BC cells ( Fig. 1g ). Moreover, JQ1 suppressed the expression of FN in a concentration-and time-dependent manner ( Fig. 1h ). Similarly, knockdown of BRD4 downregulated FN expression in BC cells ( Fig. 1i ), while overexpression of BRD4 increased the expression of FN ( Fig. S1G ). To test the in vivo effects of JQ1, we established high lung metastasis potential BC cell models [21] as summarized in Fig. S2 and named them as MDA-MB-231 LMF3 or BT-549 LMF3 cells. JQ1 could suppress the expression of FN in high lung metastasis potential BC cells also in a dose-dependent manner (Fig. S1H ). Collectively, BRD4 is upregulated in BC and modulates the malignancy of BC cells.
JQ1 suppresses the in vivo growth of PDX tumors and lung colonization of BC cells
To further examine the in vivo effects of JQ1, mice implanted with a TNBC patient-derived xenograft (PDX) model were treated with vehicle or JQ1. At the end of the experiment, tumor size, volume, and weight in the JQ1injected group were significantly lower than those measured in the control group ( Fig. 2a-d ). No significant change of body weight was observed between control and JQ1 groups (data not shown). Additionally, Ki67-positive staining, which recognizes a nuclear antigen expressed in proliferating cells, in the JQ1 group was decreased in vivo ( Fig. 2e ). This result suggested that JQ1 could inhibit in vivo growth of PDX BC.
IHC data showed that JQ1 decreased the expression of FN in the PDX model ( Fig. 2e ). To further determine the impact of JQ1 on in vivo progression, MDA-MB-231 LMF3 cells were injected into the lateral tail vein to get lung colonization. As shown in Fig. 2f , g, the number and size of lung tumors derived from JQ1-treated MDA-MB-231 LMF3 cells were significantly decreased compared to that of untreated cells. Collectively, targeted inhibition of BRD4 decreased in vivo progression of BC.
Snail is involved in BRD4-regulated malignancy of BC cells
We performed mRNA-seq in MDA-MB-231 cells treated with or without JQ1 for 24 h. Gene Set Enrichment Analysis (GSEA) revealed that the JQ1 treatment gene expression profile was negatively associated with wound healing and EMT of cancer cells ( Fig. 3a ), suggesting that JQ1 treatment suppressed wound closure and EMT. We then checked the expression of EMT-related transcription b Relative mRNA expression of BRD4 in breast and adjacent normal tissue based on data available from the TCGA database and Oncomine database with Curtis and Finak cancer, respectively; c MDA-MB-231 cells were treated with vehicle, JQ1 (1 μM), TGF-β (10 ng/ml), alone or together, for 24 h. Wound healing was recorded (left) and quantitatively analyzed (right); d BC cells were treated with vehicle or JQ1 (1 μM) for 24 h, followed by in vitro invasion checked by transwell chamber (left) and quantitatively analyzed (right); e BC cells were transfected with si-NC or si-BRD4 for 24 h. Wound healing was recorded (left) and quantitatively analyzed (right); f BC cells were transfected with vector control or a BRD4 construct for 24 h. Wound healing was recorded (left) and quantitatively analyzed (right); g BC cells were treated with vehicle, JQ1 (1 μM), TGF-β (10 ng/ml), alone or together, for 24 h. FN was checked by western blot analysis; h MDA-MB-231 cells were treated with JQ1 (1 μM) for increasing time periods (up) or increasing doses of JQ1 (down) for 24 h. FN was checked by western blot analysis; i After transfection with si-NC or si-BRD4 for 24 h, FN in BC cells was checked by western blot analysis. Data were presented as means±SD from three independent experiments. *p < 0.05, **p < 0.01 compared with control factors (EMT-TFs) including Snail, Slug, Twist, and Zeb1 in BC cells treated with JQ1. JQ1 decreased the expression of Snail, but not Slug, Twist and Zeb1, in both MDA-MB-231 ( Fig. 3b ) and BT-549 ( Fig. S3A ) cells. Further, JQ1 could decrease the expression of Snail in 2-h treatment in both MDA-MB-231 ( Fig. 3c ) and BT-549 ( Fig. S3B ) cells. The JQ1-induced rapid decrease of Snail could not be reversed even in the present of TGF-β in BC cells ( Fig. 3d ). Confocal imaging revealed that expression and nuclear accumulation of Snail was markedly decreased in JQ1treated MDA-MB-231 ( Fig. 3e ). Subcellular fractionation and western blot analysis confirmed that JQ1 significantly inhibited nuclear accumulation of Snail in BT-549 cells ( Fig. S3C ). Consistently, si-BRD4 markedly inhibited the expression of Snail in BC cells ( Fig. 3f ), while overexpression of BRD4 increased the expression and nuclear accumulation of Snail ( Fig. 3g ). Neither si-BRD2 nor si-BRD3 altered the expression of Snail in MDA-MB-231 cells ( Fig. S3D ). In the PDX model, IHC data showed that JQ1 decreased the expression of Snail in xenograft models ( Fig. 3h ).
Since Snail is known to be a potent EMT-TF able to trigger cancer progression [22] , we verified its role in JQ1suppressed migration of BC cells. The inhibitory effect of JQ1 on the migration of MDA-MB-231 cells were 46% and 71%, respectively, in cells without or with ectopic Snail expression ( Fig. 3i ), suggesting that overexpression of Snail could attenuate JQ1-inhibited cell migration. Overexpression of Snail also attenuated JQ1-suppressed FN in MDA-MB-231 ( Fig. 3j ) and BT-549 ( Fig. S3E ) cells. These results indicated that Snail is involved in BRD4-regulated malignancy of BC cells. Further, JQ1 decreased Snail mRNA in both MDA-MB-231 ( Fig. 3k ) and BT-549 ( Fig. S3F ) after 12 h treatment. Collectively, JQ1 could suppress the malignancy of BC cells via decreasing Snail expression. 
BRD4 post-translationally regulates Snail protein stability via PRKD1 in BC cells
Our data showed downregulation of Snail protein (2 h, Fig. 3c ) was much more rapidly than its effect on Snail mRNA (12 h, Fig. 3k ), suggesting that JQ1 might regulate the stability of Snail protein. Protein stability assay showed that JQ1 decreased the half-life of Snail in both MDA-MB-231 ( Fig. 4a ) and BT-549 ( Fig. S4A ) cells. In the presence of proteasome-mediated degradation inhibitor MG-132, JQ1-induced downregulation of Snail was significantly attenuated (Fig. 4b ). Further, immunoprecipitation results showed that ubiquitylation of Snail was dramatically increased in JQ1-treated MDA-MB-231 and BT-549 cells ( Fig. 4c ). Interestingly, IP results showed that Snail associated with BRD4, but their interaction was not affected by JQ1 treatment (Fig. 4d ). This was further confirmed by quantitative analysis of the pulldown versus input signals ( Fig. S4B ) and also by reciprocal immunoprecipitation with BRD4 antibody that efficiently pulled down Snail (Fig. S4C ). Since Snail could be acetylated by p300 acetyltransferase [23] , we further examined whether Snail acetylation might play a role in BRD4 interaction that could be potentially disrupted by JQ1. As shown with total Snail, acetyl-Snail and BRD4 signals in the IP were not diminished by JQ1 in both MDA-MB-231 and BT-549 cells ( Fig. 4d and Fig. S4B ), suggesting that JQ1 had no effect on either Snail acetylation or BRD4-Snail interaction.
Collectively, these data suggest that JQ1 regulates protein stability and ubiquitylation of Snail and the Snail-BRD4 interaction likely occurs independent of Snail acetylation.
GSK-3β is a major kinase that phosphorylates Snail and induces its degradation [24] , while activation of CSN2 blocks the ubiquitination and degradation of Snail [25] . However, JQ1 had no effect on GSK-3β phosphorylation and CSN2 expression ( Fig. S4D ). Further, JQ1 had no effect on subcellular localization of GSK-3β ( Fig. S4E ). In addition, the relative binding between GSK-3β and CSN2 with Snail in MDA-MB-231 and BT-549 cells was independent of JQ1 treatment (Fig. 4d ). The respective inhibitors of GSK-3β, p65, MAPK/ERK, and PI3K/Akt cannot reverse the JQ1-decreased Snail in BC cells (Fig. S4F ). These data indicated that JQ1-downregulated Snail occurs regardless of GSK-3β and NF-κB.
To systematically investigate the factors involved in JQ1-induced destabilization of Snail, we analyzed the mRNA expression of 21 factors related to post-translational regulation of Snail stability or nuclear turnover of Snail (Summarized at Table S1). JQ1 had no significant effect on most of the factors including GSK-3β and CSN2, while dramatically increased the expression of PRKD1 ( Fig. 4d, e ), which can phosphorylate Ser11 of Snail and trigger its degradation via ubiquitylation [26] . JQ1 increased the protein level of PRKD1 in BC cells in 2-h treatment (Fig. 4f ). Consistently, si-BRD4 increased PRKD1, while overexpression of BRD4 decreased PRKD1, in MDA-MB-231 cells (Fig. S4G ). However, si-BRD2 and si-BRD3 had no effect on PRKD1 expression ( Fig. S4H ). In PDX tumors, IHC data showed that JQ1 increased the expression of PRKD1 (Fig. 4g ). Overexpression of PRKD1 decreased the expression of Snail in BC cells ( Fig. S4I ), while its inhibitor CID 755763 (CID) increased the half-life of Snail protein in MDA-MB-231 cells (Fig. S4J ). To verify PRKD1-induced degradation of Snail via Ser11 phosphorylation, we mutated Snail Ser11 to Ala. The efficiency of JQ1-induced downregulation of Snail in MDA-MB-231 was attenuated by mutation of Snail at Ser11 (Fig. 4h ). Mutation of Snail Ser11 increased the half-life of Snail ( Fig. S4K ). Further, Ser 11 mutation abolished PRKD1 inhibitor (CID)-induced extension of Snail half-life ( Fig. S4K) . JQ1 significantly increased Ser11 phosphorylation of Snail in BC cells (Fig. S4L ). Knockdown of PRKD1 attenuated JQ1-induced downregulation of Snail and FN ( Fig. 4i ). Overexpression of BRD4 increased the expression of Snail while decreased its phosphorylation at Ser11; however, these effects were abolished in the present of CID (Fig. S4M ). These results indicate that BRD4regulated phosphorylation of Snail is PRKD1-dependent. It also confirmed that PRKD1 is involved in BRD4-regulated Snail protein stability and EMT in BC cells. 
BRD4 transcriptionally regulates Snail expression via Gli1 in BC cells
We showed that JQ1 suppressed mRNA expression of Snail after treatment for 12 h (Fig. 3k & S3F) . Consistently, si-BRD4 also decreased the mRNA expression of Snail after transfection for 24 h (Fig. 5a ). However, neither si-BRD2 nor si-BRD3 influenced the mRNA expression of Snail in MDA-MB-231 cells (Fig. S5A ).
This was PRKD1-independent since si-PRKD1 had no effect on Snail mRNA expression ( Fig. S5B ). JQ1 did not affect the stability of Snail precursor mRNA (pre-mRNA, Fig. S5C ) or mature mRNA (mat-mRNA, Fig. S5D ). Further, JQ1 had no effect on the nuclear export of Snail mRNA in MDA-MB-231 cells (Fig. S5E) . These results suggested that BRD4-regulated mRNA expression of Snail might not be related to RNA stability or nuclear turnover.
We then hypothesized that BRD4 might regulate the transcription of Snail in BC cells. Dual luciferase assay showed that JQ1 treatment for 12 h, but not for 1-4 h, significantly inhibited Snail promoter activity (Fig. 5b) . Further, JQ1 decreased the expression of pre-Snail mRNA after 12and 24-h treatments ( Fig. 5c ), suggesting that JQ1 could suppress the transcription of Snail after treatment for 12 h in BC cells.
We then checked the mRNA expression of 11 transcription factors potentially regulating the expression of Snail (Summarized at Table S2 ). JQ1 treatment significantly decreased the mRNA expression of Gli1, but not others, in MDA-MB-231 cells (Fig. 5d ). Further, JQ1 treatment decreased the protein expression of Gli1 after treatment for 6 h in BC cells (Fig. 5e ). Knockdown of BRD4 suppressed the mRNA expression ( Fig. 5f ) and decreased the nuclear accumulation ( Fig. 5g ) of Gli1, while overexpression of BRD4 increased the expression of Gli1 in BC cells (Fig. S5F ). Myf5 [27] and ABCG2 [28] are downstream genes directly regulated by Gli1. Downregulation of Myf5 and ABCG2 expression was observed in cells treated with JQ1 for 8 h (Fig. S5G) . IHC data showed that JQ1 decreased the expression of Gli1 in xenograft PDX models (Fig. 5h) . These results suggest that BRD4 regulates the expression, nuclear translocation, and transcriptional activity of Gli1 in BC cells.
We then overexpressed Gli1 in MDA-MB-231 cells via transfection of pcDNA/Gli1, which increased the expression of Snail and FN (Fig. 5i ). Further, JQ1-suppressed Snail expression (41% of control) was significantly attenuated in cells transfected with pcDNA/Gli1 (81% of control) (Fig. 5i) . Consistently, JQ1-suppressed FN (Fig. 5i ) and JQ1-suppressed cell migration (Fig. 5j) were both reversed by overexpression of Gli1. These data confirmed that Gli1 is involved in BRD4-regulated Snail expression and migration of BC cells.
Snail is a direct transcriptional target of Gli1 [29, 30] , but the binding of Gli1 to the Snail promoter has not been well studied. Gli1, a zinc-finger transcription factor, binds to the conserved sequence, 5′-GACCACCCA-3′, in its target promoters [31] . Analysis of the region 2.0 kb upstream of the transcription start site in the SNAI1 promoter revealed six putative Gli1-binding sites that exhibit 78% homology to the consensus Gli1-binding sequence (Fig. 5k ). ChIP-qPCR showed that binding of Gli1 to the potential binding site "e" was much greater than to the other potential sites in MDA-MB-231 cells (Fig. 5l ). We mutated bind site "e" (to CAGGAGCGG) to generate pGL3-Snail-eMut-Luc and "f" (to CAGGAGCTG) to generate pGL3-Snail-fMut-Luc, respectively (Fig. 5m ). JQ1 significantly inhibited the promoter activity of pGL3-Snail-WT-Luc and pGL3-Snail-fMut-Luc, while mutation of site "e" significantly decreased Snail promoter activity as well as its sensitivity to JQ1 treatment (Fig. 5n) . These results suggest that BRD4upregulated Gli1 directly activates the transcription of Snail via binding to its promoter-proximal site.
BRD4/Snail axis in the progression of BC
Increased expression of FN, Snail, and BRD4 was observed in MDA-MB-231 LMF3 and BT-549 LMF3 cells compared to their parental cells ( Fig. 6a) , indicating an involvement of BRD4/Snail in the progression of cancer metastasis. Further, both qRT-PCR ( Fig. S6A ) and IHC (Fig. 6b ) showed enhanced expression of Snail, BRD4, and FN in metastasized lung tumors than that in the primary tumors isolated from MMTV-PyMT mice, confirming that BRD4/Snail axis triggers the progression of BC.
Data from LinkedOmics [32] showed expression of BRD4 positively correlated (p < 0.05) with the expression of FN1 (Fig. 6c ), MMP9 (Fig. S6B ), and CDH2 (Fig. S6C ) in 880 BC patients, suggesting that BRD4 might be able to trigger EMT progression in the human body. Significant positive correlation was also observed between BRD4 and SNAI1 ( Fig. 6d ) and between SNAI1 and Gli1 (Fig. 6e ) in 880 BC patients. We then analyzed the expression of BRD4/Snail axis and their correlation with clinical characteristics of BC. The expression of BRD4 in basal BC was significantly (p < 0.01) greater than that of other subtypes e Cells were transfected with siNC or si-BRD4 for 24 h. The mRNA expression of Gli1 was checked by qRT-PCR; f Cells were transfected with siNC or si-BRD4 for 24 h. The Gli1 in subcellular fractions was checked by western blot analysis; g The expression of Gli1 in paraffinembedded sections obtained from xenografts was measured by IHC (left) and quantitatively analyzed (right); h The expression of Gli1 in paraffin-embedded sections obtained from xenografts was measured by IHC (left) and quantitatively analyzed (right); i, j MDA-MB-231 cells were transfected with pcDNA (vector) or pcDNA/Gli1 for 24 h and then treated with or without JQ1 (1 μM) for 24 h. i Protein expression was checked by western blot analysis. j Wound healing was recorded (left) and quantitatively analyzed (right); k Position in relation to the transcription start site and sequence homology to the Gli1 consensus binding sequence for putative Gli-binding sites in the human SNAI1 promoter. Red bases represent those different from the Gli-binding consensus sequence; l Binding between Gli1 transcriptional factor and the promoter of SNAI1 at the potential binding site "a" to "f" or negative site "BLK" was checked by ChIP-PCR; m Schematic representation of the mutated promoter in pGL3-Basic-Snail-luc reporter to investigate the role of Gli1 in Snail expression; n MDA-MB-231 cells were transfected with pGL3-Snail-WT-Luc, pGL3-Snail-eMut-Luc, pGL3-Snail-fMut-Luc, and pRL-TK plasmid for 24 h and then treated with or without JQ1 (1 μM) for 12 h. Results were expressed as the ratio between the activity of the reporter plasmid and pRL-TK. Data are expressed as mean±SD and similar results were obtained from three independent experiments (Fig. 6f ). In addition, expression of BRD4 in ERα-negative ( Fig. 6g ) and PRnegative ( Fig. 6h ) BCs were significantly (p < 0.05) greater than that in their positive BCs, respectively. Consistently, expression of SNAI1 in basal and HER2+BC was significantly (p < 0.01) greater than that in luminal A and B BCs (Fig. S6D ). While expression of SNAI1 in ERα- (Fig. S6E ) and PR- (Fig. S6F ) BCs was significantly (p < 0.05) greater than that in positive BCs.
Using the online bioinformatics tool Kaplan-Meier plotter [33] , we found that BC patients with increased expression of BRD4 had no significant difference of overall survival (OS) with the p value of 0.22 (Fig. 6i ). However, in lymph node-positive BC patients, increased expression of BRD4 showed significantly reduced OS (Fig. 6j) . Further, BC patients with increased expression of Snail showed significantly (p = 0.0018) reduced OS (Fig. 6k ). Together, these results suggested that BRD4/Snail axis could trigger the progression of BC.
Discussion
In this study, we examined the biological effects of targeted inhibition of BRD4 on the development of BC. We found that siRNA for BRD4 or a specific inhibitor of the BET family proteins (JQ1) suppresses the migration and EMT of BC cells via both transcriptional and post-translational downregulation of Snail (Fig. 6l ). Mechanistically, targeting BRD4 increases the expression of PRKD1 and then triggers the ubiquitination and degradation of Snail. Further, inhibition of BRD4 suppressed the transcription of Gli1, which binds the GACCACCGG sequence in the SNAI1 promoter to increase its transcription. Animal and clinical studies confirmed that BRD4/Snail pathway is critical for BC progression.
We found that targeted inhibition of BRD4 can suppress the growth and progression of BC in vitro and in vivo. The inhibitors of BET are currently in different phases of preclinical and clinical trials for treatment of multiple tumor types [5] , including NUT midline carcinoma [34] , multiple myeloma [35] , and AML [36] . BET proteins are exciting targets for BC treatment to suppress cell growth and induce apoptosis [9, 37, 38] . Recently, BRD4 was shown to also regulate TNBC migration and invasion via regulating Jag-ged1/Notch1 signaling [10] . Disrupting the interaction of BRD4 with diacetylated Twist, another EMT-TF, can suppress invasion and tumorigenicity of basal-like BC cells [11] . We found that targeted inhibition of BRD4 suppresses the migration, invasion, and EMT of BC cells via downregulation of Snail, which confers tumor cells with cancer stem cell-like traits and promotes drug resistance, tumor recurrence, and metastasis [39] .
We found that BRD4 regulates protein stability and transcription of Snail in BC cells. JQ1 can rapidly decrease Snail via increasing its ubiquitination in BC cells. Intriguingly, BRD4 interacts with Snail in BC cells; however, JQ1 had no effect on this interaction. Further, JQ1 had no effect on Snail acetylation in BC cells. The molecular nature of Snail-BRD4 interaction and whether other post-translational modification of Snail, besides the reported K187 acetylation [23] , is involved in BRD4 association remain to be further investigated. By screening the factors involved in Snail stability, we found that targeted inhibition of BRD4 increases PRKD1, which can phosphorylate Sanil at Ser11 and trigger its degradation by E3 ligase FBXO11 [26] . We did not investigate the mechanisms responsible for JQ1induced upregulation of PRKD1. Multiple signaling pathways, such as β-catenin, NF-κB, MYC/MAX, androgen receptor, and Sp1, can regulate the transcription of PRKD1 [40] . BRD4 may intact with these signaling components to regulate the expression of PRKD1, which remains to be further investigated. Gli1, a key mediator of the Hedgehog (Hh) pathway for cancer progression [41] , is responsible for BRD4-regulated transcription of Snail in BC cells. BRD4 can directly occupy GLI1 and GLI2 promoters, with a substantially decreased engagement at these sites after JQ1 treatment [42] . We further found that Gli1 can bind to the GACCACCGG sequence in the SNAI1 promoter and directly increase SNAI1 transcription. This finding contributes to our understanding of the molecular basis underpinning EMT regulation and cancer metastasis mediated by the Gli1 signaling pathway [29] .
Increased expression of BRD4 and Snail has been observed in BC, particularly for more aggressive subtypes such as lung-metastasized BC, ER-, and PR-BCs. Consistently, BRD4 is a potential therapeutic target for triple-negative [9, 43] and metastasized [10] BC in recent studies. The expression of BRD4 correlates with the expression of ECM genes that constitute prominent components of metastasis-predictive gene expression signatures [44] [45] [46] [47] . Similarly, the expression of BRD4 correlates with the expression of FN and MMPs in our present study. Our data, together with the published results, further highlight that BRD4 may be a potential target for BC therapy.
In summary, we showed that inhibition of BRD4 suppresses the dissemination and progression of BC via regulation of Snail. Our results provide strong interconnection between BRD4 and Snail to control EMT and BC cell migration and invasion, reinforcing the view that targeted inhibition of BRD4 is a promising therapeutic approach for aggressive and metastasized BC patients.
Materials and methods
Patient-derived xenograft preparation and JQ1 treatment
All animal experiments were conducted according to the guidelines of the Animal Care and Use Committee of Sun Yat-sen University. Animals were maintained in accordance to the guidelines of the American Association of Laboratory Animal Care. A patient sample (48 years old) diagnosed with stage IV (metastatic) triple-negative breast cancer (TNBC) was acquired from the First Affiliated Hospital of Sun Yat-Sen University. Surgical materials were collected, cut into pieces and implanted in Non-obese diabetic (NOD)-SCID mice with 6 h of resection to generate F1 tumors. The PDX model was deemed viable if F1 tumors demonstrated progressive growth. When F1 tumor grew to about 400 mm 3 , the xenograft was harvested, homogenized, and transplanted into the subcutaneous tissue of the NOD-SCID mice (n = 12). When the tumor was visible, mice were randomized into two groups of five mice with similar average xenograft tumor volumes and assigned to a receive treatment with JQ1 (50 mg/kg in 10% (2-hydroxypropyl)-β-cyclodextrin, b.i.d.) or vehicle only (n = 5 xenografts per arm) every day for 20 days. Tumor size was measured every 2 days in two dimensions using a caliper. Tumor volume was calculated using the formula V = 1/2 × larger diameter × (smaller diameter) 2 . At the time of killing, tumors were weighed and tumor portions were snap-frozen and stored in liquid nitrogen or fixed in 10% buffered formalin for routine histopathologic processing.
Establishment of breast cancer lung metastasis (BCLM) cell line models
The establishment of breast cancer lung metastasis cell line models was conducted according to the previous study with slight modifications as summarized in Fig. S2 [21] . Briefly, to generate lung metastasis F1 (LMF1) cells, female nude mice (4 weeks old) were injected with 2 × 10 5 viable MDA-MB-231 or BT-549 cells into the lateral tail vein in a volume of 0.1 ml. Endpoint assays were conducted at 10 weeks post injection unless significant morbidity required that the mouse should be euthanized earlier.
Then breast cancer cells metastasized to the lung were isolated, primarily cultured with medium, and named as MDA-MB-231 LMF1 or BT-549 LMF1 , respectively. LMF2 and LMF3 cells were similarly generated from their corresponding parental cells. The LMF3 cells were used for further analysis and compared to the characteristics of F0 (parental) cells.
Snail promoter activity assay
Promoter activity of Snail in cells treated with or without JQ1 was measured according to our previously described protocol [48] . Briefly, cells were transfected with pGL3-Snail-WT-Luc, pGL3-Snail-eMut-Luc, or pGL3-Snail-fMut-Luc containing the −1500/+59 sequence of the Snail promoter. Transfection efficiency was normalized by co-transfection with pRL-TK. After 24-h incubation, cells were analyzed with the Dual-Glo Luciferase Assay system (Promega). Renilla Luciferase (R-luc) was used to normalize firefly luciferase (F-luc) activity to evaluate the reporter translation efficiency.
Database (DB) analysis
The expression of BRD4 and Snail in BC and other cancers were analyzed by using data obtained from the Oncomine Database (www.oncomine.org). The sample information and expression data are available in the Gene Expression Omnibus (GEO) database [Accession nos. GSE9014 (Finak Breast) and EGAS00000000083 (Cutis Breast) at www. ncbi.nlm.nih.gov/geo].
The expression profiles of Snail, BRD4, PRKD1, and Gli1 among the subtypes of BC patients were downloaded from LinkedOmics (http://www.linkedomics.org), which is a publicly available portal that includes multi-omics data from all of 32 cancer types from The Cancer Genome Atlas (TCGA) project. The LinkedOmics web allowed flexible exploration of associations between a molecular or clinical attribute of interest and all other attributes, providing the opportunity to analyze and visualize associations between billions of attribute pairs for each cancer cohort [32] .
Statistical analysis
Results were expressed as mean ± standard deviation (SD) of three independent experiments unless otherwise specified. Data were analyzed by two-tailed unpaired Student's ttest between any two groups. These analyses were performed using GraphPad Prism Software Version 5.0 (GraphPad Software Inc., La Jolla, CA). Image J software was used to analyze the data from wound-healing, transwell and Western blot analyses. P-value of <0.05 was considered statistically significant.
